Spironolactone (n=58) | Placebo (n=55) | p Value | |||||
---|---|---|---|---|---|---|---|
Characteristic | Baseline | Follow-up | p Value | Baseline | Follow-up | p Value | ΔSpironolactone vs ΔPlacebo |
LV end-diastolic dimension, mm | 52.3±5.5 | 52.2±5.2 | 0.78 | 51.4±4.5 | 51.6±3.8 | 0.57 | 0.57 |
IVS, mm | 11.9±1.1 | 11.3±1.1 | 0.001 | 11.9±1.3 | 11.7±1.4 | 0.28 | 0.16 |
PW, mm | 9.9±1.1 | 9.5±1.0 | 0.05 | 9.7±1.4 | 9.7±1.5 | 0.86 | 0.08 |
LV mass index, g/m2.7 | 57.8±10.5 | 54.3±10.1 | 0.003 | 56.5±10.3 | 56.3±11.3 | 0.79 | 0.02 |
Left atrial dimension, mm | 43.5±4.7 | 42.3±4.1 | 0.01 | 42.8±4.4 | 42.7±4.4 | 0.81 | 0.04 |
E/e′ | 12.3±3.0 | 11.2±3.0 | 0.007 | 11.4±2.6 | 11.3±2.9 | 0.55 | 0.05 |
E/A | 0.98±0.25 | 0.99±0.23 | 0.64 | 0.97±0.17 | 0.99±0.21 | 0.26 | 0.61 |
DT, ms | 229±44 | 231±40 | 0.79 | 238±41 | 236±40 | 0.74 | 0.66 |
Sm, cm/s | 5.8±1.2 | 6.2±1.3 | 0.006 | 6.0±1.2 | 5.9±1.1 | 0.37 | 0.001 |
Em, cm/s | 5.7±1.4 | 6.6±1.4 | 0.0001 | 6.0±1.4 | 5.9±1.3 | 0.46 | 0.0001 |
Strain, % | 17.4±2.3 | 19.9±2.2 | 0.0001 | 17.6±2.1 | 17.5±2.0 | 0.44 | 0.0001 |
SR, 1/s | 1.42±0.21 | 1.60±0.20 | 0.0001 | 1.43±0.20 | 1.43±0.18 | 0.87 | 0.0001 |
IB AS, dB | −14.3±5.8 | −16.9±5.1 | 0.004 | −15.9±5.3 | −16.1±5.1 | 0.82 | 0.02 |
IB post, dB | −25.0±5.5 | −27.6±5.5 | 0.004 | −24.9±6.2 | −25.1±5.5 | 0.71 | 0.03 |
Values are mean±SD. ΔPlacebo indicates change in the placebo group during follow-up, and ΔSpironolactone the change in the spironolactone group during follow-up.
DT, diastolic flow wave; E/A, the ratio of peak early to late diastolic flow velocities; E/e′, ratio of mitral inflow early diastolic velocity to peak early diastolic mitral annular velocity; Em, myocardial peak early diastolic velocity; IB AS, calibrated integrated backscatter in the basal anteroseptum; IB post, calibrated integrated backscatter in the basal posterior wall; IVS, interventricular septal thickness; LV, left ventricular; PW, LV posterior wall thickness; Sm, peak systolic velocity; SR, peak systolic strain rate.